Melinta Therapeutics Inc., of Morristown, N.J., reported revenue of $16 million and $12 million, respectively, for the three-month periods ended June 30, 2019, and 2018. Read More
Agile Therapeutics Inc., of Princeton, N.J., said the underwriters of its public offering of common stock have exercised in full their option to purchase an additional 1.89 million shares at 95 cents each, bringing the total number of shares sold to 14.52 million and total gross proceeds to approximately $13.8 million. Read More
Neoleukin Therapeutics Inc., of Seattle, completed its merger with Aquinox Pharmaceuticals Inc., of Vancouver, British Columbia. Aquinox will be renamed Neoleukin and now trades under the new ticker symbol NLTX on the Nasdaq. Read More
BOGOTA, Colombia - Grupo Laboratorios Imperiales Pharma SA de C.V. (Laboratorios Imperiales), from Jiutepec, Mexico, the distributor of measles-rubella (MR) and measles, mumps and rubella (MMR) vaccines manufactured by Serum Institute of India Pvt. Ltd., was banned from signing public contracts with Mexico's public entities for 27 months and fined MX$1.088 million (US$55,478) after it breached two public contracts with the country's Secretariat of Health to provide the country with vaccines. Read More
PERTH, Australia – San Diego-based Okogen Inc. is taking its clinical trial program to Australia where it will test its lead compound OKG-0301 for acute adenoviral conjunctivitis in the phase II (RUBY) trial. Read More
Analysts had questions aplenty for Nektar Therapeutics Inc. about cancer drug candidate bempegaldesleukin ("bempeg," NKTR-214) after the firm made known some apparent manufacturing problems with the compound, a CD122-preferential interleukin-2 pathway agonist designed to stimulate the patient's own immune system and fight various cancer types. Read More
Kala Pharmaceuticals Inc. said it would look to data from a third phase III trial of its dry eye disease candidate, KPI-121 0.25%, to satisfy the request, in an FDA complete response letter (CRL), for efficacy data from an additional trial to support its NDA. The study, called STRIDE (Short Term Relief In Dry Eye) 3, is already underway with Kala targeting a top-line readout by year-end to support a resubmission in the first half of 2020. Read More
LONDON - The great and good of British science have given a less than lukewarm reception to government plans to preserve the status of U.K. research by setting up a new fast track visa system to attract top scientists post-Brexit. Read More
The advisory committee meeting (adcom) that slowed progress for Amarin Corp. and its pending supplemental new drug application (sNDA) for expanding the labeling of Vascepa (icosapent ethyl) was a shock not only to the company but to investors, too, as the stock (NASDAQ:AMRN) took a battering Friday. Read More
We're working to enhance BioWorld's news services by moving to a brand-new platform later this year. Upgrades will include: same-day news delivery, improved functionality, easier accessibility on all devices, more analysis and dynamic data visualization. We value your opinion on these changes. Please take 2 minutes to complete this short survey to help guide our work: https://www.surveymonkey.com/r/Q5TK8JL Read More
The blood-brain barrier prevents many drugs from entering the brain. Unfortunately, the same cannot be said for tumor cells. The brain is one of the most frequent locations for cancer metastases, which are then extremely challenging to treat. Now, researchers at the University of California at Los Angeles have developed an encapsulation technique that allowed the delivery of the monoclonal antibody Rituxan (rituximab) to brain metastases of a mouse xenograft model of non-Hodgkin lymphoma. Read More
